

# CITATION REPORT

List of articles citing

**Senile systemic amyloidosis: clinical features at presentation and outcome**

**DOI: 10.1161/jaha.113.000098**

**Journal of the American Heart Association, 2013, 2, e000098.**

**Source:** <https://exaly.com/paper-pdf/56380094/citation-report.pdf>

**Version:** 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
245	Amyloid heart disease (part 1): Epidemiology, types, clinical features and investigations. <b>2014</b> , 9, 281-286		
244	Amyloid heart disease (part 2): Management and specific treatments. <b>2014</b> , 9, 330-335		
243	Transthyretin aggregate-specific antibodies recognize cryptic epitopes on patient-derived amyloid fibrils. <b>2014</b> , 17, 97-104		15
242	Cancer risk in amyloidosis patients in Sweden with novel findings on non-Hodgkin lymphoma and skin cancer. <b>2014</b> , 25, 511-8		8
241	Immunohistochemical and morphometric analysis of immunoglobulin light-chain immunoreactive amyloid in psammoma bodies of the human choroid plexus. <b>2014</b> , 89, 71-8		1
240	Novel drugs targeting transthyretin amyloidosis. <b>2014</b> , 11, 50-7		47
239	Impact of clinical and echocardiographic characteristics on occurrence of cardiac events in cardiac amyloidosis as proven by endomyocardial biopsy. <i>International Journal of Cardiology</i> , <b>2014</b> , 176, 753-9	3.2	11
238	Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. <b>2014</b> , 2, 113-22		212
237	Application of a parametric display of two-dimensional speckle-tracking longitudinal strain to improve the etiologic diagnosis of mild to moderate left ventricular hypertrophy. <b>2014</b> , 27, 888-95		54
236	Echocardiographic assessment of the cardiac amyloidoses. <i>Circulation Journal</i> , <b>2015</b> , 79, 721-34	2.9	25
235	Distinctive Patterns of Transthyretin Amyloid in Salivary Tissue: A Clinicopathologic Study of 92 Patients With Amyloid-containing Minor Salivary Gland Biopsies. <b>2015</b> , 39, 1035-44		13
234	Green tea extract as a treatment for patients with wild-type transthyretin amyloidosis: an observational study. <b>2015</b> , 9, 6319-25		48
233	Cardiac amyloidosis in a heart transplant patient - A case report and retrospective analysis of amyloidosis evolution. <b>2015</b> , 4, 60-4		3
232	The transthyretin amyloidoses: advances in therapy. <b>2015</b> , 91, 439-48		28
231	Current indications, strategies, and outcomes with cardiac transplantation for cardiac amyloidosis and sarcoidosis. <b>2015</b> , 20, 584-92		10
230	Cardiac amyloidosis: where are we today?. <b>2015</b> , 278, 126-44		48
229	Extracellular volume quantification by dynamic equilibrium cardiac computed tomography in cardiac amyloidosis. <b>2015</b> , 9, 585-92		75

228	Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. <b>2015</b> , 36, 2585-94		470
227	Differential Myocyte Responses in Patients with Cardiac Transthyretin Amyloidosis and Light-Chain Amyloidosis: A Cardiac MR Imaging Study. <b>2015</b> , 277, 388-97		92
226	Improving strategies for the diagnosis of cardiac amyloidosis. <b>2015</b> , 13, 945-61		3
225	Atrial fibrillation in amyloidotic cardiomyopathy: prevalence, incidence, risk factors and prognostic role. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , <b>2015</b> , 22, 147-55	2.7	72
224	Cardiac findings and events observed in an open-label clinical trial of tafamidis in patients with non-Val30Met and non-Val122Ile hereditary transthyretin amyloidosis. <b>2015</b> , 8, 117-27		49
223	Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes. <b>2015</b> , 8, 519-26		90
222	Bifunctional crosslinking ligands for transthyretin. <b>2015</b> , 5, 150105		2
221	Diagnosis, Prognosis, and Therapy of Transthyretin Amyloidosis. <b>2015</b> , 66, 2451-2466		250
220	Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs. <i>Heart Failure Reviews</i> , <b>2015</b> , 20, 163-78	5	133
219	Pathophysiology and treatment of cardiac amyloidosis. <b>2015</b> , 12, 91-102		85
218	Clinical, ECG and echocardiographic clues to the diagnosis of TTR-related cardiomyopathy. <b>2016</b> , 3, e000289		47
217	The Prevalence and Management of Systemic Amyloidosis in Western Countries. <b>2016</b> , 2, 10-9		69
216	ECG low QRS voltage and wide QRS complex predictive of centenarian 360-day mortality. <b>2016</b> , 38, 44		4
215	Transthyretin Cardiac Amyloidosis in Black Americans. <b>2016</b> , 9, e002558		35
214	Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. <b>2016</b> , 133, 2404-12		792
213	AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy. <b>2016</b> , 68, 1323-41		277
212	Current and future treatment of amyloid diseases. <b>2016</b> , 280, 177-202		65
211	Occult Transthyretin Cardiac Amyloid in Severe Calcific Aortic Stenosis: Prevalence and Prognosis in Patients Undergoing Surgical Aortic Valve Replacement. <b>2016</b> , 9,		133

210	[Cardiac amyloidosis: How to recognize them and manage them?]. <b>2016</b> , 45, 845-855	5
209	V122I TTR Cardiac Amyloidosis in Patients of African Descent: Recognizing a Missed Disease or the Dog That Didn't Bark?. <b>2016</b> , 9,	4
208	Transthyretin Cardiac Amyloidosis in Older Americans. <b>2016</b> , 22, 996-1003	33
207	Pilot study for left ventricular imaging phenotype of patients over 65 years old with heart failure and preserved ejection fraction: the high prevalence of amyloid cardiomyopathy. <b>2016</b> , 32, 1403-1413	38
206	Role of imaging in cardiac amyloidosis: An ongoing challenge. <b>2016</b> , 23, 1364-1367	1
205	Heart Failure Resulting From Age-Related Cardiac Amyloid Disease Associated With Wild-Type Transthyretin: A Prospective, Observational Cohort Study. <b>2016</b> , 133, 282-90	157
204	Wild-Type Transthyretin Amyloid Cardiomyopathy: A Missed Cause of Heart Failure With Preserved Ejection Fraction With Evolving Treatment Implications. <b>2016</b> , 133, 245-7	23
203	Healthy aging and myocardium: A complicated process with various effects in cardiac structure and physiology. <i>International Journal of Cardiology</i> , <b>2016</b> , 209, 167-75	3.2 37
202	Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis. <b>2016</b> , 5, 1-25	91
201	Systemic amyloidosis. <b>2016</b> , 387, 2641-2654	475
200	The Utility of Tc-DPD Scintigraphy in the Diagnosis of Cardiac Amyloidosis: An Australian Experience. <b>2017</b> , 26, 1183-1190	17
199	Blood Proteomic Profiling in Inherited (ATTRm) and Acquired (ATTRwt) Forms of Transthyretin-Associated Cardiac Amyloidosis. <b>2017</b> , 16, 1659-1668	13
198	Senile cardiac amyloidosis: Clinical manifestations and non-invasive diagnostic approach. <b>2017</b> , 58, 60-64	1
197	Challenging the myths of cardiac amyloidosis. <b>2017</b> , 38, 1909-1912	8
196	Design and Rationale of the Phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial). <b>2017</b> , 10,	48
195	Transthyretin Cardiac Amyloidosis in Older Adults: Optimizing Cardiac Imaging to the Corresponding Diagnostic and Management Goal. <b>2017</b> , 11, 1	5
194	Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis. <b>2017</b> , 38, 1905-1908	92
193	Carpal Tunnel Biopsy Identifying Transthyretin Amyloidosis. <b>2017</b> , 69, 2051	4

192	Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis. <b>2017</b> , 135, 1357-1377		214
191	Prognostic utility of the Perugini grading of 99mTc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid. <b>2017</b> , 18, 1344-1350		76
190	Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths. <b>2017</b> , 38, 1895-1904		163
189	Dangerous relationships: aortic stenosis and transthyretin cardiac amyloidosis. <b>2017</b> , 38, 2888-2889		5
188	A case study of likely wild-type cardiac transthyretin amyloidosis causing rapid deterioration. <b>2017</b> , 18, 138-142		1
187	Treatment With Tafamidis Slows Disease Progression in Early-Stage Transthyretin Cardiomyopathy. <b>2017</b> , 11, 1179546817730322		23
186	Transthyretin Cardiac Amyloidosis. <i>Current Cardiology Reports</i> , <b>2017</b> , 19, 97	4.2	32
185	Safety and efficacy of a TTR specific antisense oligonucleotide in patients with transthyretin amyloid cardiomyopathy. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , <b>2017</b> , 24, 219-225	2.7	53
184	Diagnosis and Treatment of Transthyretin Cardiac Amyloidosis. Progress and Hope. <b>2017</b> , 70, 991-1004		23
183	Magnetic Resonance in Transthyretin Cardiac Amyloidosis. <b>2017</b> , 70, 466-477		176
182	Diagnóstico y tratamiento de la amiloidosis cardiaca por transtiretina. Progreso y esperanza. <b>2017</b> , 70, 991-1004		50
181	Prevalence of Monoclonal Gammopathy in Wild-Type Transthyretin Amyloidosis. <b>2017</b> , 92, 1800-1805		45
180	Identification and Assessment of Cardiac Amyloidosis by Myocardial Strain Analysis of Cardiac Magnetic Resonance Imaging. <i>Circulation Journal</i> , <b>2017</b> , 81, 1014-1021	2.9	21
179	TTR (Transthyretin) Stabilizers Are Associated With Improved Survival in Patients With TTR Cardiac Amyloidosis. <b>2018</b> , 11, e004769		54
178	Effects of dietary salt on gene and protein expression in brain tissue of a model of sporadic small vessel disease. <b>2018</b> , 132, 1315-1328		4
177	Use of Serum Transthyretin as a Prognostic Indicator and Predictor of Outcome in Cardiac Amyloid Disease Associated With Wild-Type Transthyretin. <b>2018</b> , 11, e004000		38
176	Cardiac amyloidosis. <b>2018</b> , 18, s30-s35		53
175	Cardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment. <b>2018</b> , 28, 10-21		126

174	A new staging system for cardiac transthyretin amyloidosis. <b>2018</b> , 39, 2799-2806		211
173	Diagnostic utility of cardiac troponin T level in patients with cardiac amyloidosis. <i>ESC Heart Failure</i> , <b>2018</b> , 5, 27-35	3-7	32
172	ATTR Cardiac Amyloidosis: Classification, Diagnosis, and Management. <b>2018</b> , 242-256		
171	Wild-type transthyretin cardiac amyloidosis (ATTRwt-CA), previously known as senile cardiac amyloidosis: clinical presentation, diagnosis, management and emerging therapies. <b>2018</b> , 10, 2034-2045		15
170	OBSOLETE: Cardiac Magnetic Resonance Imaging in Heart Failure. <b>2018</b> ,		
169	OBSOLETE: ATTR Cardiac Amyloidosis: Classification, Diagnosis, and Management. <b>2018</b> ,		
168	Diagnosis of Cardiac Amyloidosis: Clinical and Echocardiographic Features. <b>2018</b> , 11, 1		
167	Management of the elderly patient with AL amyloidosis. <b>2018</b> , 58, 48-56		13
166	Cardiac Amyloidosis: Updates in Imaging. <i>Current Cardiology Reports</i> , <b>2019</b> , 21, 108	4-2	26
165	Estimating the Prevalence of Transthyretin Amyloid Cardiomyopathy in a Large In-Hospital Database in Japan. <b>2019</b> , 8, 297-316		9
164	[Cardiac involvement in storage diseases : Role of genetic diagnostics]. <b>2019</b> , 44, 461-474		
163	Combination of Commonly Examined Parameters Is a Useful Predictor of Positive Tc-Labeled Pyrophosphate Scintigraphy Findings in Elderly Patients With Suspected Transthyretin Cardiac Amyloidosis. <i>Circulation Journal</i> , <b>2019</b> , 83, 1698-1708	2-9	19
162	Transthyretin cardiac amyloidosis: an update on diagnosis and treatment. <i>ESC Heart Failure</i> , <b>2019</b> , 6, 1128-1139	3-7	55
161	Neurological Manifestations of Transthyretin-Related Amyloidosis. <b>2019</b> ,		2
160	Diagnostic performance of imaging investigations in detecting and differentiating cardiac amyloidosis: a systematic review and meta-analysis. <i>ESC Heart Failure</i> , <b>2019</b> , 6, 1041-1051	3-7	32
159	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging. <b>2019</b> , 26, 2065-2123		107
158	Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis. <b>2019</b> , 12, e006075		171
157	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2-Evidence Base and Standardized Methods of Imaging. <b>2019</b> , 25, e1-e39		56

156	Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. <b>2019</b> , 73, 2872-2891	289
155	The epidemiology of amyloidosis in Queensland, Australia. <b>2019</b> , 186, 829-836	2
154	Cardiac Amyloidosis A Rare Disease in Older Adults Hospitalized for Heart Failure?. <b>2019</b> , 12, e006169	7
153	Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis. <b>2019</b> , 140, 16-26	124
152	Use of Ventilatory Efficiency Slope as a Marker for Increased Mortality in Wild-Type Transthyretin Cardiac Amyloidosis. <b>2019</b> , 124, 122-130	5
151	EXPRESS: Riociguat for the treatment of transthyretin cardiac amyloidosis - Data from a named patient use program in Austria. <b>2019</b> , 2045894019849394	1
150	Correction to: Reference Ranges for the Size of the Fetal Cardiac Outflow Tracts From 13 to 36 Weeks Gestation: A Single-Center Study of Over 7000 Cases. <b>2019</b> , 12, e000025	
149	Nine contemporary therapeutic directions in heart failure. <b>2019</b> , 11, e011150	1
148	Spinal Stenosis in Familial Transthyretin Amyloidosis. <b>2019</b> , 6, 267-270	7
147	Carpal tunnel syndrome and spinal canal stenosis: harbingers of transthyretin amyloid cardiomyopathy?. <b>2019</b> , 108, 1324-1330	47
146	A pair of peptides inhibits seeding of the hormone transporter transthyretin into amyloid fibrils. <b>2019</b> , 294, 6130-6141	16
145	Heart failure with preserved ejection fraction, atrial fibrillation, and the role of senile amyloidosis. <b>2019</b> , 40, 1287-1293	27
144	Role of echocardiography in assessing cardiac amyloidoses: a systematic review. <b>2019</b> , 17, 64-75	3
143	Wild-type ATTR amyloidosis may be associated with unexpected death among the elderly. <b>2019</b> , 41, 101634	6
142	Diagnosis and Treatment of Cardiac Amyloidosis Related to Plasma Cell Dyscrasias. <b>2019</b> , 37, 487-495	3
141	Best Practices for Prognostic Evaluation of a Patient With Transthyretin Amyloid Cardiomyopathy. <i>JACC: CardioOncology</i> , <b>2019</b> , 1, 273-279	3.8 3
140	Cardiac amyloidosis. <b>2019</b> , 7, 21-32	6
139	Imaging cardiac innervation in amyloidosis. <b>2019</b> , 26, 174-187	13

138	Cardiomyopathy and autonomic neuropathy in hereditary amyloidosis: Defining the cart and the horse. <b>2020</b> , 27, 1785-1786		1
137	Cardiac amyloidosis: The starched heart. <b>2020</b> , 27, 133-136		6
136	Systemic Amyloidosis: a Contemporary Overview. <b>2020</b> , 59, 304-322		10
135	Cardiac Amyloidosis. <b>2020</b> , 301-310.e3		1
134	Integrated diagnostic approach to wild-type transthyretin cardiac amyloidosis with the use of high-sensitivity cardiac troponin T measurement and Tc-pyrophosphate scintigraphy. <i>Journal of Cardiology</i> , <b>2020</b> , 75, 12-19	3	13
133	Technetium pyrophosphate scintigraphy with cadmium zinc telluride cameras is a highly sensitive and specific imaging modality to diagnose transthyretin cardiac amyloidosis. <b>2020</b> , 27, 371-380		8
132	The current status of quantitative SPECT/CT in the assessment of transthyretin cardiac amyloidosis. <b>2020</b> , 27, 1464-1468		11
131	New developments in diagnosis, risk assessment and management in systemic amyloidosis. <b>2020</b> , 40, 100636		21
130	Amyloid Cardiomyopathy. <b>2020</b> , 29, 575-583		8
129	Clinical characteristics and prognosis of cardiac amyloidosis defined by mass spectrometry-based proteomics in an Australian cohort. <b>2020</b> ,		0
128	Clinical characteristics and natural history of wild-type transthyretin amyloid cardiomyopathy in Japan. <i>ESC Heart Failure</i> , <b>2020</b> , 7, 2829-2837	3.7	10
127	Diagnosis and treatment of cardiac amyloidosis: an interdisciplinary consensus statement. <b>2020</b> , 132, 742-761		13
126	Educational Case: Orbital B-Cell Lymphoma With Amyloid Deposition. <b>2020</b> , 7, 2374289520934089		1
125	The use of cardiovascular magnetic resonance for the assessment of left ventricular hypertrophy. <b>2020</b> , 10, 568-582		3
124	Coexistent transthyretin amyloid cardiomyopathy and monoclonal gammopathy: Diagnostic challenges and prognostic implications. <b>2020</b> , 1		2
123	A serine protease secreted from <i>Bacillus subtilis</i> cleaves human plasma transthyretin to generate an amyloidogenic fragment. <b>2020</b> , 3, 764		6
122	Glycosylation of Serum Clusterin in Wild-Type Transthyretin-Associated (ATTRwt) Amyloidosis: A Study of Disease-Associated Compositional Features Using Mass Spectrometry Analyses. <b>2020</b> , 59, 4367-4378		4
121	Usefulness of relative apical longitudinal strain index to predict positive Tc-labeled pyrophosphate scintigraphy findings in advanced-age patients with suspected transthyretin amyloid cardiomyopathy. <b>2020</b> , 37, 1774-1783		2



120	Tafamidis: A Novel Treatment for Transthyretin Amyloid Cardiomyopathy. <b>2020</b> , 28, 156-160		1
119	DISCOVERY: prevalence of transthyretin (T) mutations in a US-centric patient population suspected of having cardiac amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , <b>2020</b> , 27, 223-230	2.7	12
118	Outcomes in patients with cardiac amyloidosis and implantable cardioverter-defibrillator. <b>2020</b> , 22, 1216-1223		10
117	Amyloidosis Diagnosed in Solid Organ Transplant Recipients. <b>2020</b> , 104, 415-420		4
116	Diagnosis and Treatment of Hereditary Transthyretin Amyloidosis (hATTR) Polyneuropathy: Current Perspectives on Improving Patient Care. <b>2020</b> , 16, 109-123		31
115	Amyloid Proteins and Peripheral Neuropathy. <b>2020</b> , 9,		4
114	Diagnostic imaging of cardiac amyloidosis. <b>2020</b> , 17, 413-426		39
113	Diagnostic amyloid proteomics: experience of the UK National Amyloidosis Centre. <b>2020</b> , 58, 948-957		11
112	Diagnostic delay in wild type transthyretin cardiac amyloidosis - A clinical challenge. <i>International Journal of Cardiology</i> , <b>2020</b> , 304, 138-143	3.2	17
111	Cardiac Amyloidosis: Overlooked, Underappreciated, and Treatable. <b>2020</b> , 71, 203-219		36
110	Diagnosis of Transthyretin Amyloid Cardiomyopathy. <b>2020</b> , 9, 85-95		10
109	When to Suspect a Diagnosis of Amyloidosis. <b>2020</b> , 143, 304-311		17
108	Outcome of patients with severe AL amyloidosis and biopsy-proven renal involvement ineligible for bone marrow transplantation. <b>2021</b> , 34, 231-240		1
107	Prognostic implications of left ventricular myocardial work indices in cardiac amyloidosis. <b>2021</b> , 22, 695-704		17
106	Single-Dose Pharmacokinetics and Pharmacodynamics of Transthyretin Targeting N-acetylgalactosamine-Small Interfering Ribonucleic Acid Conjugate, Vutrisiran, in Healthy Subjects. <b>2021</b> , 109, 372-382		31
105	Transthyretin amyloid cardiomyopathy in women: frequency, characteristics, and diagnostic challenges. <i>Heart Failure Reviews</i> , <b>2021</b> , 26, 35-45	5	15
104	Unveiling outcomes in coexisting severe aortic stenosis and transthyretin cardiac amyloidosis. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 250-258	12.3	23
103	Natural history and impact of treatment with tafamidis on major cardiovascular outcome-free survival time in a cohort of patients with transthyretin amyloidosis. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 264-274	12.3	10

102	Prevalence of wild type transthyretin cardiac amyloidosis in a heart failure clinic. <i>ESC Heart Failure</i> , <b>2021</b> , 8, 745-749	3.7	13
101	Association of Low Plasma Transthyretin Concentration With Risk of Heart Failure in the General Population. <b>2021</b> , 6, 258-266		2
100	Comparison of Patterns of Coronary Artery Disease in Patients With Heart Failure by Cardiac Amyloidosis Status. <b>2021</b> , 27, 31-35		1
99	Amyloid arthropathy in smoldering myeloma: Do not take it lightly. <b>2021</b> , 15, 100242		0
98	How to Identify Transthyretin Cardiac Amyloidosis at an Early Stage. <b>2021</b> , 60, 1-7		
97	Practice in Medicine: A Rare Presentation of Dilated Cardiomyopathy with Intermittent Complete Heart Block. <i>Indian Journal of Cardiovascular Disease in Women WINCARS</i> , <b>2021</b> , 06, 059-067	0.1	1
96	Neuromuscular amyloidosis: Unmasking the master of disguise. <b>2021</b> , 64, 23-36		8
95	The Importance of Multimodality Imaging in the Diagnosis and Management of Patients with Infiltrative Cardiomyopathies: An Update. <b>2021</b> , 11,		2
94	Protein aggregation and self assembly in Health and Disease. <b>2021</b> , 18,		
93	Use of biomarkers to diagnose and manage cardiac amyloidosis. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 217-230	12.3	12
92	Increased thickness of lumbar spine ligamentum flavum in wild-type transthyretin amyloidosis. <b>2021</b> , 84, 33-37		4
91	Screening for ATTR amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awareness. <i>Heart Failure Reviews</i> , <b>2021</b> , 1	5	12
90	Canadian Guidelines for Hereditary Transthyretin Amyloidosis Polyneuropathy Management. <b>2021</b> , 1-12		1
89	Clinical approach to genetic testing in amyloid cardiomyopathy: from mechanism to effective therapies. <i>Current Opinion in Cardiology</i> , <b>2021</b> , 36, 309-317	2.1	1
88	Clinical Practice Guidelines for diagnosis of amyloidosis: Part 1/3 Year 2020. <b>2021</b> , 78, 74-82		2
87	Clinical Amyloid Typing by Proteomics: Performance Evaluation and Data Sharing Between Two Centres. <b>2021</b> , 26,		2
86	Updates in Cardiac Amyloidosis Diagnosis and Treatment. <b>2021</b> , 23, 47		5
85	Light chain and transthyretin cardiac amyloidosis: Clinical characteristics, natural history and prognostic factors. <b>2021</b> , 156, 369-378		

84	Light chain and transthyretin cardiac amyloidosis: Clinical characteristics, natural history and prognostic factors. <b>2021</b> , 156, 369-378			2
83	Impact of Delayed Diagnosis and Misdiagnosis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM): A Targeted Literature Review. <b>2021</b> , 10, 141-159			6
82	Coronary Artery Disease and Amyloidosis: Can One Alter the Other?. <b>2021</b> , 27, 36-37			
81	Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update. <b>2021</b> , 96, 1546-1577			8
80	Tenosynovial and Cardiac Transthyretin Amyloidosis in Japanese Patients Undergoing Carpal Tunnel Release. <b>2021</b> , 3, 338-344			0
79	The integration of genetically-regulated transcriptomics and electronic health records highlights a pattern of medical outcomes related to increased hepatic Transthyretin expression.			
78	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2-Evidence Base and Standardized Methods of Imaging. <b>2021</b> , 14, e000029			12
77	Wild-type TTR amyloidosis among patients with unexplained heart failure and systolic LV dysfunction. <b>2021</b> , 16, e0254104			1
76	Association between spinal stenosis and wild-type ATTR amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , <b>2021</b> , 1-8	2.7		3
75	Lumbar ligamentum flavum burden: Evaluating the role of ATTRwt amyloid deposition in ligamentum flavum thickness at all lumbar levels. <b>2021</b> , 206, 106708			2
74	Cardiac Amyloidosis [An Underdiagnosed Cause of Heart Failure with Preserved Ejection Fraction] Updated Diagnosis and Treatment Options. <b>2021</b> , 31, 283-302			1
73	Advances in Diagnosis and Treatment of Cardiac and Renal Amyloidosis. <b>2021</b> , 39, 389-402			2
72	Wild-Type Transthyretin Amyloidosis in Female Patients - Consideration of Sex Differences. <b>2021</b> , 3, 465-471			4
71	Systemische Amyloidosen [Diagnostik und Therapie. <i>Kardiologie Up2date</i> , <b>2021</b> , 17, 235-247			0
70	Position Statement on Diagnosis and Treatment of Cardiac Amyloidosis - 2021. <b>2021</b> , 117, 561-598			15
69	A real-world study on diagnosis and prognosis of light-chain cardiac amyloidosis in Southern China. <b>2021</b> , 21, 452			
68	Long-term Electrocardiographic Follow-up in Patients with Light-chain Cardiac Amyloidosis. <b>2021</b> ,			0
67	Diagnosis and supportive therapeutic management of cardiac light chain amyloidosis: cardiologist's perspective. <b>2021</b> , 14, 89-97			2

66	Practical recommendations for the diagnosis and management of transthyretin cardiac amyloidosis. <i>Heart Failure Reviews</i> , <b>2021</b> , 26, 861-879	5	4
65	Cardiac sympathetic denervation in wild-type transthyretin amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , <b>2020</b> , 27, 237-243	2.7	4
64	Exploring Mechanisms of Inhibition of Amyloid Seeding of Transthyretin.		1
63	IgG Conformer's Binding to Amyloidogenic Aggregates. <b>2015</b> , 10, e0137344		3
62	Cardiac Amyloid - An Update. <b>2015</b> , 10, 113-117		3
61	Arrhythmias in Cardiac Amyloidosis. <b>2018</b> , 9, 3051-3057		22
60	Unfolding Cardiac Amyloidosis -From Pathophysiology to Cure. <b>2019</b> , 26, 2865-2878		9
59	Transthyretin Cardiac Amyloidosis and Aortic Stenosis: Connection and Therapeutic Implications. <b>2020</b> , 16, 221-230		3
58	Cardiac Amyloidosis and its New Clinical Phenotype: Heart Failure with Preserved Ejection Fraction. <b>2017</b> , 109, 71-80		19
57	Nationwide prevalence and characteristics of transthyretin amyloid cardiomyopathy in Sweden. <b>2021</b> , 8,		4
56	Conduction abnormalities and role of cardiac pacing in cardiac amyloidosis: A systematic review. <b>2021</b> , 44, 2092		0
55	Pathophysiological pathways in patients with heart failure and atrial fibrillation. <b>2021</b> ,		0
54	ATTR Amyloidosis. <b>2016</b> , 254-257		
53	Proteolytic truncation of human transthyretin linked to amyloidosis is mediated by a trypsin like enzyme: In vitro demonstration using model peptides. <b>2016</b> , 4, 5		
52	Cardiac Magnetic Resonance Imaging in Heart Failure. <b>2018</b> , 451-462		
51	Hepatic amyloidosis leading to hepatic venular occlusive disease and Budd-Chiari syndrome: A case report. <b>2019</b> , 7, 3282-3288		0
50	Amyloidosis and the lung. <b>2019</b> , 296-318		
49	Prediction of Medium-Term Mortality in Japanese Patients With Wild-Type Transthyretin Amyloidosis. <b>2020</b> , 2, 314-321		2

48	The role of serial Tc-DPD scintigraphy in monitoring cardiac transthyretin amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , <b>2021</b> , 1-12	2.7	1
47	Sex-related differences in the clinical characteristics of wild-type transthyretin amyloidosis cardiomyopathy. <i>Journal of Cardiology</i> , <b>2022</b> , 79, 50-57	3	0
46	Acquired Cardiomyopathies. <b>2020</b> , 171-190		
45	Difficulties in the Diagnosis of Cardiac Amyloidosis and Treatment Options: Case Report. <i>Vnitřní Lékarství</i> , <b>2020</b> , 66, e34-e40	0.3	
44	ATTR Amyloidosis: Current and Emerging Management Strategies: State-of-the-Art Review. <i>JACC: CardioOncology</i> , <b>2021</b> , 3, 488-505	3.8	7
43	Senile transthyretin cardiac amyloidosis in patients with plasma cell dyscrasias: importance of cardiac biopsy for making the correct diagnosis. <b>2014</b> , 1,		4
42	Proteotoxicity and Autophagy in Neurodegenerative and Cardiovascular Diseases. <b>2022</b> , 219-237		
41	Incidence, clinical characteristics, and diagnostic approach in transthyretin amyloid cardiomyopathy: The Kumamoto Cardiac Amyloidosis Survey.. <i>Journal of Cardiology</i> , <b>2022</b> ,	3	
40	Nutrient-sensing amyloid metastasis.. <i>BioFactors</i> , <b>2022</b> ,	6.1	1
39	ATTR Epidemiology, Genetics, and Prognostic Factors.. <i>Methodist DeBakey Cardiovascular Journal</i> , <b>2022</b> , 18, 17-26	2.1	3
38	Cardiac amyloidosis. <i>Current Opinion in Cardiology</i> , <b>2022</b> , Publish Ahead of Print,	2.1	0
37	Clinical features and predictors of atrial fibrillation in patients with light-chain or transthyretin cardiac amyloidosis.. <i>ESC Heart Failure</i> , <b>2022</b> ,	3.7	0
36	Epidémiologie des amyloses cardiaques. <i>Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique</i> , <b>2022</b> , 2022, 2-6	0	
35	Suspicion, screening, and diagnosis of wild-type transthyretin amyloid cardiomyopathy: a systematic literature review.. <i>ESC Heart Failure</i> , <b>2022</b> ,	3.7	0
34	Circulating biomarkers in diagnosis and management of cardiac amyloidosis: a review for internist.. <i>Internal and Emergency Medicine</i> , <b>2022</b> , 1	3.7	3
33	Syncope in patients with transthyretin amyloid cardiomyopathy: clinical features and outcomes.. <i>Postgraduate Medicine</i> , <b>2022</b> ,	3.7	1
32	Annual Cardiovascular-Related Hospitalization Days Avoided with Tafamidis in Patients with Transthyretin Amyloid Cardiomyopathy.. <i>American Journal of Cardiovascular Drugs</i> , <b>2022</b> , 1	4	0
31	Isolated amyloidosis of the gastro-intestinal tract.. <i>Acta Gastro-Enterologica Belgica</i> , <b>2022</b> , 85, 80-84	0.6	

30	Amyloid seeding as a disease mechanism and treatment target in transthyretin cardiac amyloidosis.. <i>Heart Failure Reviews</i> , <b>2022</b> , 1	5	2
29	Transthyretin Amyloid Cardiomyopathy in a Young Female. <i>Indian Journal of Cardiovascular Disease in Women WINCARS</i> , <b>2021</b> , 06, 267-274	0.1	
28	The integration of genetically-regulated transcriptomics and electronic health records highlights a pattern of medical outcomes related to increased hepatic expression.. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , <b>2021</b> , 1-10	2.7	
27	Phenotypic heterogeneity and diagnostic features of transthyretin amyloidosis with polyneuropathy. <i>Nervno-Myshechnye Bolezni</i> , <b>2021</b> , 11, 12-36	0.2	
26	Global and Regional Variations in Transthyretin Cardiac Amyloidosis: A Comparison of Longitudinal Strain and 99mTechnetium Pyrophosphate Imaging.. <i>Journal of Nuclear Medicine Technology</i> , <b>2021</b> ,	1.1	1
25	Treatment of Transthyretin Amyloid Cardiomyopathy: The Current Options, the Future, and the Challenges.. <i>Journal of Clinical Medicine</i> , <b>2022</b> , 11,	5.1	4
24	Routine ambulatory heart rhythm monitoring for detection of atrial arrhythmias in transthyretin cardiac amyloidosis.. <i>International Journal of Cardiology</i> , <b>2022</b> ,	3.2	0
23	New Advanced Imaging Parameters and Biomarkers-A Step Forward in the Diagnosis and Prognosis of TTR Cardiomyopathy.. <i>Journal of Clinical Medicine</i> , <b>2022</b> , 11,	5.1	2
22	Imaging-Guided Treatment for Cardiac Amyloidosis.. <i>Current Cardiology Reports</i> , <b>2022</b> , 1	4.2	0
21	Prevalence, characteristics, and mortality of patients with transthyretin amyloid cardiomyopathy in the Nordic countries.. <i>ESC Heart Failure</i> , <b>2022</b> ,	3.7	1
20	Assessment and Management of Older Patients With Transthyretin Amyloidosis Cardiomyopathy: Geriatric Cardiology, Frailty Assessment and Beyond. <i>Frontiers in Cardiovascular Medicine</i> , <b>2022</b> , 9,	5.4	
19	Early Experience of Tafamidis Treatment in Japanese Patients With Wild-Type Transthyretin Cardiac Amyloidosis From the Kochi Amyloidosis Cohort. <i>Circulation Journal</i> , <b>2022</b> ,	2.9	1
18	Speichererkrankungen mit kardialer Manifestation. <i>Kardiologie Up2date</i> , <b>2022</b> , 18, 173-189	0	
17	Prevalence and Clinical Outcomes of Transthyretin Amyloidosis: A Systematic Review and Meta-analysis. <i>European Journal of Heart Failure</i> ,	12.3	2
16	Santalol Isomers Inhibit Transthyretin Amyloidogenesis and Associated Pathologies in <i>Caenorhabditis elegans</i> . <i>Frontiers in Pharmacology</i> , 13,	5.6	
15	Wild type cardiac amyloidosis: is it time to order a nuclear technetium pyrophosphate SPECT imaging study?. <i>International Journal of Cardiovascular Imaging</i> ,		
14	Impact of Tafamidis on Survival in a Real World Community-Based Cohort. <b>2022</b> , 101358		0
13	Update on Disease-Specific Biomarkers in Transthyretin Cardiac Amyloidosis.		

12	Red flags for the diagnosis of cardiac amyloidosis: simple suggestions to raise suspicion and achieve earlier diagnosis. <b>2022</b> , 23, 493-504	0
11	Identification of wild-type transthyretin cardiac amyloidosis in patients with carpal tunnel syndrome surgery ( CACTuS).	0
10	Cryo-EM structure of an ATTRwt amyloid fibril from systemic non-hereditary transthyretin amyloidosis. <b>2022</b> , 13,	1
9	Current and potential therapeutic strategies for transthyretin cardiac amyloidosis. 2,	0
8	Noninvasive Diagnostics of Renal Amyloidosis: Current State and Perspectives. <b>2022</b> , 23, 12662	0
7	Analysis of lumbar spine stenosis for identification of amyloid.	0
6	Oral Therapy for the Treatment of Transthyretin-Related Amyloid Cardiomyopathy. <b>2022</b> , 23, 16145	0
5	Amyloidosis: What does pathology offer? The evolving field of tissue biopsy. 9,	0
4	Current approaches to the diagnosis and management of amyloidosis. <b>2022</b> , 52, 2046-2067	1
3	Amylose □transthyrēine. <b>2022</b> , 45-52	0
2	Prevalence of transthyretin amyloidosis among heart failure patients with preserved ejection fraction in Japan.	1
1	Prognostic Factors and Survival of Chinese Patients with Cardiac Amyloidosis. <b>2023</b> , 2023, 1-8	0